Evolution of mantle cell lymphoma therapy: advancing frontline precision

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Mantle cell lymphoma (MCL) frontline treatment historically relied on age-dependent chemoimmunotherapy and autologous stem cell transplantation.
• These traditional methods, while effective, carry significant risks of treatment-related morbidity and disease relapse.

Purpose of the Study:

• To review the evolving therapeutic landscape of MCL.
• To highlight the integration of novel targeted agents in frontline treatment strategies.
• To discuss the role of measurable residual disease (MRD) in guiding therapy.

Main Methods:

• Literature review of recent clinical trials and studies on MCL treatment.
• Analysis of emerging targeted therapies and immunotherapies.
• Evaluation of MRD monitoring techniques and their clinical implications.

Main Results:

• Novel targeted agents are challenging the necessity of traditional consolidative transplants in MCL.
• Treatment de-escalation, including reduced chemotherapy or avoidance, is becoming feasible.
• MRD assessment aids in identifying early relapses and personalizing treatment duration.

Conclusions:

• Frontline MCL therapy is moving towards biological precision, integrating targeted and immune-engaging agents.
• Optimized maintenance strategies aim to deepen responses and prolong survival.
• The goal is to maximize long-term remission while minimizing treatment toxicity.